dolutegravir + efavirenz + emtricitabine + tenofovir

This is a hypothetical or non-standard four-drug antiretroviral regimen combining dolutegravir, efavirenz, emtricitabine, and tenofovir. Each component targets HIV replication through different mechanisms: - Dolutegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing viral DNA from integrating into the host genome[6]. - Efavirenz is a non-nucleoside reverse transcriptase inhibitor that binds to reverse transcriptase and inhibits its activity[2][7]. - Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors that act as chain terminators during viral DNA synthesis[2][3]. Standard clinical practice does not combine both an NNRTI (efavirenz) and an INSTI (dolutegravir) in one regimen due to overlapping toxicities, lack of added benefit, and increased risk of side effects. However, combinations of three drugs among these agents are widely used for first-line treatment of HIV infection in adults and children weighing at least 40 kg[1][5].

Brand names

None known for the four-drug combination; individual components have brand names such as Tivicay (dolutegravir), Sustiva (efavirenz), Emtriva (emtricitabine), and Viread (tenofovir disoproxil fumarate) or Descovy (tenofovir alafenamide).

Other names

None known for the four-drug combination.